Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 86.33M P/E - EPS this Y -1,621.40% Ern Qtrly Grth -
Income -54.93M Forward P/E -1.04 EPS next Y 12.20% 50D Avg Chg -3.00%
Sales 13.42M PEG - EPS past 5Y - 200D Avg Chg -10.00%
Dividend N/A Price/Book 0.36 EPS next 5Y - 52W High Chg -70.00%
Recommedations 2.00 Quick Ratio 14.58 Shares Outstanding 38.55M 52W Low Chg 11.00%
Insider Own 3.46% ROA -15.20% Shares Float 28.30M Beta -0.39
Inst Own 49.84% ROE -23.29% Shares Shorted/Prior 159.22K/11.75K Price 2.25
Gross Margin -237.35% Profit Margin - Avg. Volume 19,622 Target Price 9.31
Oper. Margin -7,717.96% Earnings Date Nov 14 Volume 16,281 Change 0.00%
About Vaccitech plc

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

VACC Chatroom

User Image DocPharm Posted - 09/25/24

$VACC base?

User Image DocPharm Posted - 08/26/24

$BRNS $VACC $ABUS Still no attention on this, quite intriguing

User Image johnnygogogo Posted - 5 months ago

$VACC liquidation sale on aisle 1. Trading at approx 38% cash value.

User Image Ulong Posted - 5 months ago

$VACC "Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections" - The development of VTP-300 in chronic Hepatitis B (CHB) and VTP-1000 in celiac disease will be prioritized. - The pipeline prioritization is expected to result in a reduction in workforce of approximately 25% and an estimated extension to the cash runway into the second quarter of 2026. Read more: https://www.globenewswire.com/en/news-release/2024/06/12/2897874/0/en/Barinthus-Bio-Announces-Strategic-Pipeline-Prioritization-Following-Positive-Interim-Data-from-VTP-300-in-Chronic-Hepatitis-B-Virus-Infections.html

User Image johnnygogogo Posted - 5 months ago

$VACC why isn’t the ticker symbol updated to BRNS? And why does this trade at 50% cash?

User Image RollingDollars Posted - 5 months ago

$VACC $BRNS

User Image RollingDollars Posted - 5 months ago

$VACC $BRNS

User Image frontiere Posted - 6 months ago

$NVAX exited rest, tiny tracker position remaining for a close watch… $BRNS Barinthus (ex Vaccitech $VACC ) exited April position at flat as $NVAX is now core focus in vaccines / H5N1 basket. Added to $MRNA short, ready to short more on spikes.

User Image Ulong Posted - 7 months ago

$VACC $BRNS "Barinthus Bio Announces Data From Phase 1B/2 Apollo Trial Of Vtp-200 In Persistent HPV Infections" - Primary safety endpoint met; VTP-200 was generally well-tolerated, with no treatment-related grade 3 or higher adverse events (AEs) or serious AEs (SAEs). - Positive trends in clearance rate for both high-risk (hr)HPV (60%, Group 2) and cervical lesions (67%,Groups 2 and 5), were observed in the groups receiving the highest ChAdOx dose. - Pooled data from the five different active dose groups demonstrated no statistically significant improvement in either hrHPV or cervical lesion clearance in comparison to the placebo group. https://investors.barinthusbio.com/news-releases/news-release-details/barinthus-bio-announces-topline-data-phase-1b2-apollo-trial-vtp

User Image Ulong Posted - 7 months ago

$VACC Status/Anticipated upcoming milestones in Q2 and H1:

User Image DocPharm Posted - 7 months ago

$ABUS $VACC BARINTHUS is the perfect storm a brewin’ ?

User Image thebenchwarmers Posted - 7 months ago

$ABUS On another note..... Anybody know why $BRNS / $VACC is up 22% today? That's who ABUS has the VTP-300 trial with.

User Image Ulong Posted - 02/28/24

$VACC ST doesn't show ticker $BRNS (Barinthus), formerly known als $VACC (Vaccitech). It's now a💎👑💰

User Image cctranscripts Posted - 10 months ago

Vaccitech: Barinthus Bio Provides A Financial Update And Announces Anticipated 2024 Corporate M https://www.conferencecalltranscripts.org/summary/?id=12846784 $VACC

User Image Ulong Posted - 10 months ago

$VACC "Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones" - Cash runway anticipated to be extended from Q2 2025 to Q4 2025 - Data from multiple Phase 1 and 2 clinical trials expected in 2024 https://investors.barinthusbio.com/news-releases/news-release-details/barinthus-bio-provides-financial-update-and-announces

User Image Ulong Posted - 12/24/23

$VACC "New partnership aims to advance vaccine against MERS coronavirus ·CEPI to invest funding of up to $34.8 million to Barinthus Bio in addition to funds previously committed to the University of Oxford to develop and stockpile a ready reserve of emergency MERS vaccine candidate, VTP-500. ·VTP-500 project with Barinthus Bio and University of Oxford uses tested ChAdOx1 platform. ·If successful in Phase II trials, this will progress VTP-500 significantly towards regulatory approval and doses could be rapidly deployed in a clinical trial setting in response to a substantial outbreak." https://www.sec.gov/Archives/edgar/data/1828185/000110465923128782/tm2333622d1_ex99-1.htm

User Image Ulong Posted - 12/24/23

$VACC "On December 21, 2023, the Company issued a joint press release with Oxford and CEPI titled “New partnership aims to advance emergency vaccine against MERS coronavirus.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K." https://www.sec.gov/ix?doc=/Archives/edgar/data/1828185/000110465923128782/tm2333622d1_8k.htm

User Image cctranscripts Posted - 12/22/23

Vaccitech: Barinthus Bio Forward-Looking Statements https://www.conferencecalltranscripts.org/summary/?id=12818476 $VACC

User Image risenhoover Posted - 12/22/23

$VACC / Vaccitech plc - ADR files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 BARINTHUS BIOTH https://fintel.io/doc/sec-barinthus-biotherapeutics-plc-1828185-8k-2023-december-22-19713-543?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

User Image Ulong Posted - 12/22/23

$VACC This morning 20% ​​increase in the German premarket. Will it fall again? 🤔 Strange actions here. Shorts can't keep it down forever😁

User Image Ulong Posted - 11 months ago

$VACC Hohoho🎅, good vibrations here in Premarket (Germany, in €). Could become a nice day📈

User Image Ulong Posted - 11 months ago

@jacksparo Seems like they're all too busy🥳, so much unbelievable chances today. The $COTY and crashing & recovering like crazy $VACC ($BRNS) made my day😅 I wonder what will be tomorrow, there can be no more cash in the world, all spent today😂

User Image MarketsBestPicks Posted - 1 year ago

$AIRE $TENX $VACC $AMC $VCNX Ready to rocket….

User Image DocPharm Posted - 1 year ago

$ABUS $VACC data immaculate Deal for p3 imminent

User Image Ulong Posted - 1 year ago

$VACC I wish I had bought more... over 20% since then

User Image Last10K Posted - 1 year ago

$VACC just filed with the SEC a Earnings Release and a Financial Exhibit https://last10k.com/sec-filings/VACC/0001104659-23-116280.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=VACC

User Image Last10K Posted - 1 year ago

Last10K highlighted 52 positive and negative remarks in the $VACC 10-Q filed today. See them in the Quarterly Report: https://last10k.com/sec-filings/VACC/0001410578-23-002303.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=sentiment&utm_term=vacc

User Image Last10K Posted - 1 year ago

$VACC just filed a 10-Q Quarterly Report with 6 financial statements and 42 disclosures: https://last10k.com/sec-filings/vacc/0001410578-23-002303.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=vacc

User Image Last10K Posted - 1 year ago

$VACC just filed with the SEC a Regulated Disclosure and a Financial Exhibit https://last10k.com/sec-filings/VACC/0001104659-23-116327.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=VACC

User Image cctranscripts Posted - 1 year ago

Vaccitech: Barinthus Bio Presents Interim Data From Phase 2B Hbv003 Trial And Phase 2A Ab-729-2 https://www.conferencecalltranscripts.org/summary/?id=12693673 $VACC

Analyst Ratings
HC Wainwright & Co. Buy Nov 28, 23
Alliance Global Partners Buy Sep 25, 23
Morgan Stanley Equal-Weight Sep 25, 23
Morgan Stanley Overweight Aug 18, 23
HC Wainwright & Co. Buy Jun 13, 23
Morgan Stanley Overweight May 16, 23
HC Wainwright & Co. Buy Mar 29, 23
HC Wainwright & Co. Buy Mar 27, 23
HC Wainwright & Co. Buy Mar 21, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Scheeren Joseph Director Director Jun 26 Buy 2.44 10,000 24,400 23,000 06/28/23
Wright Robin Director Director May 25 Buy 2.6627 13,750 36,612 48,256 06/01/23
Ellis Christopher Chief Operating Offi.. Chief Operating Officer Aug 17 Option 0 2,824 2,250 08/19/22
Ellis Christopher Chief Operating Offi.. Chief Operating Officer Aug 17 Sell 4.8 2,824 13,555 75 08/19/22
Griffiths Graham Chief Business Offic.. Chief Business Officer Aug 17 Sell 4.7620 500 2,381 114,209 08/19/22
Griffiths Graham Chief Business Offic.. Chief Business Officer Aug 12 Sell 4.50 5,000 22,500 118,329 08/15/22
Ellis Christopher Chief Operating Offi.. Chief Operating Officer Jun 28 Option 0 5 80 07/15/22
Ellis Christopher Chief Operating Offi.. Chief Operating Officer Jun 28 Sell 6 5 30 75 07/15/22
Griffiths Graham Chief Business Offic.. Chief Business Officer Jun 23 Option 0 7,338 123,237 07/15/22
Griffiths Graham Chief Business Offic.. Chief Business Officer Jun 23 Sell 5.28 8 42 123,229 07/15/22